IRWD EBITDA | IRONWOOD PHARMACEUTICALS, INC.

IRONWOOD PHARMACEUTICALS, INC. (IRWD) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income $79.31M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income $72.57M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income $75.48M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income $45.32M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2009-12-31 to 2025-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	$79.31M	(m)	$113.04M	(m)	(m)	$58.28M*	(m)	$22.42M	$11.31M	$22.44M
2026-03-31	Reported	(m)	$72.57M	(m)	$106.51M	(m)	(m)	$5.12M	(m)	$21.94M	$12.03M	$24.40M
2025-09-30	Reported	(m)	$75.48M	(m)	$122.06M	(m)	$2.00K*	$47.58M*	(m)	$22.47M	$21.91M	$27.94M
2025-06-30	Reported	(m)	$45.32M	(m)	$85.24M	(m)	$2.00K*	-$15.07M*	(m)	$23.37M	$16.80M	$14.22M
2025-03-31	Reported	(m)	-$29.11M	(m)	$41.14M	(m)	$31.00K	$19.95M	(m)	$27.43M	$24.26M	$1.11M
2024-09-30	Reported	(m)	$25.64M	(m)	$91.59M	(m)	$16.00K*	$9.88M*	(m)	$29.83M	$36.11M	$13.72M
2024-06-30	Reported	(m)	$24.98M	(m)	$94.40M	(m)	$58.00K*	$33.47M*	(m)	$30.39M	$36.96M	$19.74M
2024-03-31	Reported	(m)	$11.02M	(m)	$74.88M	(m)	$68.00K	$44.98M	(m)	$25.82M	$37.60M	$9.12M
2023-09-30	Reported	(m)	$40.02M	(m)	$113.74M	(m)	$49.00K*	$32.46M*	(m)	$32.98M	$36.05M	$17.98M
2023-06-30	Reported	(m)	-$1.08B	(m)	$107.38M	(m)	$0.00*	$34.96M*	(m)	$34.58M	$52.48M	$13.26M
2023-03-31	Reported	(m)	$60.10M	(m)	$104.06M	(m)	$13.00K	$80.17M	(m)	$12.85M	$31.12M	$20.15M
2022-09-30	Reported	(m)	$68.47M	(m)	$108.64M	(m)	$66.00K*	$69.09M*	(m)	$11.54M	$28.62M	$19.59M
2022-06-30	Reported	(m)	$55.66M	(m)	$97.23M	(m)	$88.00K*	$61.37M*	(m)	$11.45M	$30.12M	$16.70M
2022-03-31	Reported	(m)	$57.85M	(m)	$97.53M	(m)	$9.00K	$64.12M	(m)	$10.82M	$28.86M	$17.66M
2021-09-30	Reported	(m)	$65.17M	(m)	$103.75M	(m)	(m)	$75.06M*	(m)	$10.91M	$27.74M	$3.83M
2021-06-30	Reported	(m)	$65.10M	(m)	$104.03M	(m)	(m)	$48.57M*	(m)	$12.16M	$27.05M	-$336.93M
2021-03-31	Reported	(m)	$45.40M	(m)	$88.84M	(m)	(m)	$73.69M	(m)	$15.48M	$27.65M	$432.00K
2020-09-30	Reported	(m)	$45.62M	(m)	$103.47M	(m)	$0.00*	$53.63M*	$0.00*	$21.69M	$34.93M	$1.39M
2020-06-30	Reported	(m)	$32.71M	(m)	$89.43M	(m)	$376.00K*	$20.09M*	$0.00*	$22.08M	$34.64M	$0.00
2020-03-31	Reported	(m)	$13.23M	(m)	$79.94M	(m)	$1.44M	$43.60M	$2.24M	$28.03M	$36.45M	(m)
2019-09-30	Reported	(m)	$65.89M	(m)	$131.17M	(m)	$3.08M*	$34.77M*	$506.00K	$27.55M	$40.92M	(m)
2019-06-30	Reported	(m)	$21.58M	(m)	$102.22M	(m)	-$1.79M*	-$9.24M*	$11.31M	$28.76M	$43.25M	(m)
2019-03-31	Reported	(m)	-$16.93M	(m)	$68.73M	(m)	$3.23M	-$42.38M	$1.04M	$32.20M	$49.09M	(m)
2018-12-31	Reported	$28.91M	(m)	(m)	(m)	22.12%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$145.19M*	-$146.57M	$1.39M*	$65.69M	-221.03%*	-$1.35M*	-$26.58M*	$4.62M	$29.16M	$50.54M	(m)
2018-06-30	Reported	-$13.01M*	-$14.68M	$1.67M*	$81.11M	-16.04%*	-$62.00K*	-$22.69M*	$4.07M	$23.19M	$59.77M	(m)
2018-03-31	Reported	-$34.08M	(m)	(m)	(m)	-49.28%	$1.51M	-$30.89M	$2.61M	$36.51M	$59.50M	(m)
2017-12-31	Reported	$84.59M	(m)	(m)	(m)	89.79%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$17.67M*	-$19.43M	$1.76M*	$86.83M	-20.35%*	$1.46M*	-$31.24M*	$6.08M	$37.06M	$61.77M	(m)
2017-06-30	Reported	-$39.08M*	-$41.01M	$1.93M*	$65.08M	-60.06%*	$709.00K*	-$32.45M*	$3.50M	$37.34M	$57.79M	(m)
2017-03-31	Reported	-$36.8M	(m)	(m)	(m)	-70.53%	$1.04M	-$27.85M	$531.00K	$33.70M	$55.60M	(m)
2016-12-31	Reported	-$3.54M	(m)	(m)	(m)	-4.05%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$26.09M*	-$28.29M	$2.20M*	(m)	(m)	$1.39M*	-$645.00K*	(m)	$37.53M	$44.99M	(m)
2016-06-30	Reported	-$12.83M*	-$15.31M	$2.49M*	(m)	(m)	$615.00K*	(m)	(m)	$31.68M	$36.92M	(m)
2016-03-31	Reported	$865,000.00	(m)	(m)	(m)	1.31%	$1.01M	(m)	(m)	$31.84M	$36.17M	(m)
2015-12-31	Reported	-$3.03M	(m)	(m)	(m)	-5.68%	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	-$23.40M*	-$26.18M	$2.79M*	(m)	(m)	$416.00K*	(m)	(m)	$25.83M	$30.44M	(m)
2015-06-30	Reported	-$38.86M*	-$42.01M	$3.15M*	(m)	(m)	$853.00K*	(m)	(m)	$28.65M	$32.95M	(m)
2015-03-31	Reported	-$25.18M	(m)	(m)	(m)	-87.02%	$1.99M	-$35.78M	(m)	$26.64M	$30.35M	(m)
2014-12-31	Reported	-$30.17M	(m)	(m)	(m)	-79.25%	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	-$33.57M*	-$36.74M	$3.17M*	(m)	(m)	$476.00K*	-$38.68M*	(m)	$25.12M	$28.54M	(m)
2014-06-30	Reported	-$52.09M*	-$55.12M	$3.03M*	(m)	(m)	$729.00K*	-$36.21M*	(m)	$22.14M	$29.30M	(m)
2014-03-31	Reported	-$41.21M	(m)	(m)	(m)	-282.15%	$1.29M	-$57.89M	(m)	$27.14M	$29.92M	(m)
2013-12-31	Reported	-$43.66M	(m)	(m)	(m)	-867.74%	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	-$53.48M*	-$56.55M	$3.07M*	(m)	(m)	$984.00K*	-$57.95M*	(m)	$23.02M	$30.26M	(m)
2013-06-30	Reported	-$57.09M*	-$59.88M	$2.79M*	(m)	(m)	$1.95M*	-$80.14M*	(m)	$24.09M	$30.87M	(m)
2013-03-31	Reported	-$86.05M	(m)	(m)	(m)	-2643.47%	$2.94M	-$93.18M	(m)	$32.75M	$33.37M	(m)
2012-12-31	Reported	-$41.1M	(m)	(m)	(m)	-152.32%	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	$50.64M*	$47.61M	$3.03M*	(m)	(m)	$3.56M*	$38.99M*	(m)	$23.45M	$22.85M	(m)
2012-06-30	Reported	-$38.02M*	-$40.83M	$2.81M*	(m)	(m)	$2.40M*	-$43.11M*	(m)	$32.24M	$20.10M	(m)
2012-03-31	Reported	-$32.96M	(m)	(m)	(m)	-269.07%	$4.64M	-$43.06M	(m)	$29.51M	$16.32M	(m)
2011-12-31	Reported	-$4.36M	(m)	(m)	(m)	-13.55%	(m)	(m)	(m)	(m)	(m)	(m)
2011-09-30	Reported	-$19.33M*	-$21.62M	$2.29M*	(m)	(m)	$566.00K*	-$25.41M*	(m)	$22.91M	(m)	$3.00K
2011-06-30	Reported	-$16.05M*	-$18.95M	$2.90M*	(m)	(m)	$2.00M*	(m)	(m)	$19.41M	(m)	(m)
2011-03-31	Reported	-$16.41M	(m)	(m)	(m)	-160.29%	$3.47M	(m)	(m)	$19.55M	(m)	(m)
2010-12-31	Reported	-$10.88M	(m)	(m)	(m)	-64.86%	(m)	(m)	(m)	(m)	(m)	(m)
2010-09-30	Reported	-$14.64M*	-$16.16M	$1.53M*	(m)	(m)	$6.49M*	-$22.78M*	(m)	$18.74M	(m)	-$2.94M
2010-06-30	Reported	(m)	-$17.31M	(m)	(m)	(m)	(m)	(m)	(m)	$19.90M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$99.6M	(m)	(m)	(m)	33.63%	$34.00K	$127.04M	(m)	$95.14M	$82.26M	$46.01M
2024-12-31	Reported	$94.32M	(m)	(m)	(m)	26.84%	$142.00K	$103.55M	(m)	$111.42M	$144.27M	$64.32M
2023-12-31	Reported	-$944.23M	(m)	(m)	(m)	-213.27%	$273.00K	$183.43M	(m)	$1.10B	$158.31M	$83.49M
2022-12-31	Reported	$251.74M	(m)	(m)	(m)	61.31%	$136.00K	$273.76M	(m)	$44.27M	$115.99M	$77.36M
2021-12-31	Reported	$233.76M	(m)	(m)	(m)	56.50%	$265.00K	$261.89M	(m)	$70.41M	$111.13M	-$327.79M
2020-12-31	Reported	$145.24M	(m)	(m)	(m)	37.29%	$1.84M	$168.84M	$3.14M	$88.06M	$140.00M	$2.69M
2019-12-31	Reported	$125.72M	(m)	(m)	(m)	29.35%	$7.19M	$10.72M	$23.88M	$115.04M	$172.45M	$0.00
2018-12-31	Reported	-$146.77M	(m)	(m)	(m)	-42.34%	$351.00K	-$70.88M	$32.75M	$101.06M	$219.68M	$0.00
2017-12-31	Reported	-$8.96M	(m)	(m)	(m)	-3.00%	$2.80M	-$100.75M	$19.10M	$88.14M	$231.18M	$0.00
2016-12-31	Reported	-$41.59M	(m)	(m)	(m)	-15.18%	$4.21M	-$25.93M	$1.87M	$139.49M	$173.28M	$0.00
2015-12-31	Reported	-$90.46M	(m)	(m)	(m)	-60.48%	$4.05M	-$106.93M	(m)	$108.75M	$125.25M	$0.00
2014-12-31	Reported	-$157.04M	(m)	(m)	(m)	-205.45%	$3.54M	-$155.57M	(m)	$101.89M	$118.33M	$0.00
2013-12-31	Reported	-$240.27M	(m)	(m)	(m)	-1050.10%	$9.59M	-$273.36M	(m)	$102.38M	$123.23M	(m)
2012-12-31	Reported	-$61.44M	(m)	(m)	(m)	-40.89%	$13.98M	-$69.63M	(m)	$113.47M	$92.54M	(m)
2011-12-31	Reported	-$56.14M	(m)	(m)	(m)	-85.23%	$9.68M	-$75.24M	(m)	$86.09M	$45.92M	$3.00K
2010-12-31	Reported	-$54.61M	(m)	(m)	(m)	-124.51%	$17.22M	-$67.90M	(m)	$77.45M	$27.17M	-$2.94M
2009-12-31	Reported	-$56.05M	(m)	(m)	(m)	-163.32%	$3.52M	-$3.44M	(m)	$76.10M	(m)	-$296.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Nuvectis Pharma, Inc. (NVCT)	United States	$0.705B	-17.53
Climb Bio, Inc. (CLYM)	United States	$0.683B	-13.03
Verastem, Inc. (VSTM)	United States	$0.706B	-1.71
ZEVRA THERAPEUTICS, INC. (ZVRA)	United States	$0.668B	14.61
COLLEGIUM PHARMACEUTICAL, INC (COLL)	United States	$0.737B	24.57
BlossomHill Therapeutics, Inc. (BLSM)	United States	$0.647B
Faeth Therapeutics, Inc. (FTH)	United States	$0.750B
Shattuck Labs, Inc. (STTK)	United States	$0.634B	-13.30
Neurogene Inc. (NGNE)		$0.625B	-4.46
Design Therapeutics, Inc. (DSGN)	United States	$0.766B	-12.78